WEST Search History

updated

Hide Items | Restore | Clear | Cancel

DATE: Thursday, May 27, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND	
☐	L1	$carbamoly or carbamoyl$ or dcchol or dc-chol	55947
☐	L2	pylori or pyloris or pylor or pylon or pylroidis or pyloridis or pylorum or hpylori or h-pylori or helicobacter or helicobacters	14201
☐	L3	urease or urea or ure-a or ure-b or ureb	212303
☐	L4	(L3 or l2) and l1	11617
☐	L5	(L3 or l2) same l1	2099
☐	L6	l1 same l2	25
☐	L7	6082820.pn.	2
☐	L8	L7 and l2	0

END OF SEARCH HISTORY

Generate Collection | Print

Search Results - Record(s) 1 through 25 of 25 returned.

☐ 1. 20040033240. 09 Jun 03. 19 Feb 04. Immunological combinations for prophylaxis and therapy of helicobacter pylori infection. Guy, Bruno, et al. 424/234.1; A61K039/02.

☐ 2. 20040029118. 03 Jun 02. 12 Feb 04. Streptococcus pneumoniae polynucleotides and sequences. Kunsch, Charles A., et al. 435/6; 702/20 C12Q001/68 G06F019/00 G01N033/48 G01N033/50.

☐ 3. 20040009474. 24 May 01. 15 Jan 04. Novel human polynucleotides and polypeptides encoded thereby. Leach, Martin D., et al. 435/6; 435/183 435/320.1 435/325 435/69.1 530/350 536/23.2 C12Q001/68 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/47.

☐ 4. 20030203915. 07 Apr 03. 30 Oct 03. Nitric oxide donors, compositions and methods of use related applications. Fang, Xinqin, et al. 514/253.01; 514/275 514/305 514/484 514/508 544/322 544/360 558/480 A61K031/496 A61K031/505 A61K031/325 A61K031/215.

☐ 5. 20030044783. 09 Mar 01. 06 Mar 03. Human genes and gene expression products. Williams, Lewis T., et al. 435/6; 435/183 435/320.1 435/325 435/69.1 530/350 530/388.1 536/23.2 C12Q001/68 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/435 C07K016/40.

☐ 6. 20020197605. 18 Dec 00. 26 Dec 02. Novel Polynucleotides. Nakagawa, Satoshi, et al. 435/6; 435/287.2 435/91.2 C12Q001/68 C12P019/34 C12M001/34.

☐ 7. 20020032323. 30 Oct 97. 14 Mar 02. STREPTOCOCCUS PNEUMONIAE POLYNUCLEOTIDES AND SEQUENCES. KUNSCH, CHARLES A., et al. 536/23.7; 435/252.3 435/320.1 435/69.1 536/24.32 C12P021/02 C07H021/04 C12N001/21 C12N015/74.

☐ 8. 6706508. 02 Nov 99; 16 Mar 04. Ornithine carbamoyltransferase. Brown; James Raymond, et al. 435/193; 424/94.5 435/15 530/350. C12N009/10 C12Q001/48 A61K038/53 C07K017/00.

☐ 9. 6623764. 31 Aug 99; 23 Sep 03. Biodegradable targetable microparticle delivery system. Sokoll; Kenneth K., et al. 424/501; 424/78.37 528/318 528/329.1. A61K009/16 A61K047/34 C08G063/08.

☐ 10. 6414003. 09 Nov 00; 02 Jul 02. Oxazolone derivatives and their use as anti-helicobacter pylori agents. Kanamaru; Tsuneo, et al. 514/376; 514/340. A61K031/422.

☐ 11. 6169102. 10 Sep 98; 02 Jan 01. Oxazolone derivatives and their use as anti-Helicobacter pylori agent. Kanamaru; Tsuneo, et al. 514/376; 548/225. A61K031/422 C07D413/06.

☐ 12. 6165763. 30 Oct 97; 26 Dec 00. Ornithine carbamoyltransferase. Brown; James Raymond, et al. 435/193; 435/252.3 435/320.1 435/325 536/23.2. C12N009/10 C12N001/20 C12N015/00 C07H021/04.

☐ 13. 6126938. 04 Feb 98; 03 Oct 00. Methods for inducing a mucosal immune response. Guy; Bruno, et al. 424/184.1; 424/199.1 424/234.1 424/278.1 424/282.1 424/812 514/44. A61K039/00.

☐ 14. 5814634. 17 Apr 97; 29 Sep 98. Alkylenediamine derivative anti-ulcer drug and antibacterial drug. Nishino; Chikao, et al. 514/237.8; 514/331 544/160 544/169 544/400 546/233 546/234. A61K031/535 C07D265/30 C07D211/32.

☐ 15. JP411147892A. 23 Apr 98. 02 Jun 99. PHYSIOLOGICALLY ACTIVE SUBSTANCE, ITS PRODUCTION AND AGENT. MIYAGAWA, KENICHIRO, et al. C07F009/6512; A61K038/00 A61K038/00 C07K005/093.

☐ 16. JP410152487A. 18 Mar 97. 09 Jun 98. N-ACYLPIPERAZINE DERIVATIVE, ANTIBACTERIAL AGENT AND ANTIULCER AGENT. NISHINO, CHIKAO, et al. C07D317/60; A61K031/495 A61K031/495 C07D213/72 C07D213/79 C07D295/10 C07D295/14 C07D317/58.

☐ 17. FR002762787A1. 30 Apr 97. 06 Nov 98. Helicobacter-derived immunogen for use as vaccine. GUY, BRUNO, et al. A61K039/39; A61K039/02.

☐ 18. WO009848836A1. 30 Apr 98. 05 Nov 98. ANTI-HELICOBACTER VACCINE COMPOSITION COMPRISING A TH1 ADJUVANT. GUY, BRUNO, et al. A61K039/106;.

☐ 19. EP000875501A2. 06 Apr 98. 04 Nov 98. Alkylenediamine derivative, anti-ulcer drug, and antibacterial drug. NISHINO, CHIKAO, et al. C07C235/50; C07C235/60 C07C237/34 C07D213/82 C07D213/81 A61K031/165 A61K031/44.

☐ 20. EP000832887A1. 30 Sep 97. 01 Apr 98. N-acylpiperazine derivative, anti-ulcer drug, and antibacterial drug. NISHINO, CHIKAO, et al. C07D317/68; C07D213/80 C07D295/18 A61K031/495.

☐ 21. WO009749703A2. 24 Jun 97. 31 Dec 97. OXAZOLONE DERIVATIVES AND THEIR USE AS ANTI-HELICOBACTER PYLORI AGENT. KANAMARU, TSUNEO, et al. C07D413/06; C07D263/48 C07D413/14 C12P017/16 A61K031/42.

☐ 22. EP000802196A1. 18 Apr 97. 22 Oct 97. Alkylenediamine derivative, antiulcer drug, and antibacterial drug. NISHINO, CHIKAO, et al. C07D295/12; A61K031/445 A61K031/50 A61K031/535.

☐ 23. WO009608247A1. 13 Sep 95. 21 Mar 96. ANTI-HELICOBACTER AGENT. YONEZAWA, KENJI, et al. A61K031/34;.

☐ 24. WO 9848836A. Helicobacter-derived immunogen for use as vaccine - containing extract of Quillaja saponaria, cationic lipid and/or glyco-lipo-peptide as adjuvant. GUY, B, et al. A61K039/02 A61K039/106 A61K039/39 A61K045/00 A61K047/00 A61P031/04 A61K039/02 A61K047:26 A61K047:42.

☐ 25. EP 531228A. New antisecretory and antibacterial thiourea derivs. - for treatment of peptic ulcers and Helicobacter Pylori infections. ISOZAKI, M, et al. A61K031/335 A61K031/36 A61K031/395 A61K031/40 A61K031/435 A61K031/445 C07D211/06 C07D217/66 C07D317/48 C07D317/50 C07D317/58 C07D317/66 C07D319/18 C07D405/12 C07D405/14.

Generate Collection | Print

Terms	Documents

L1 same L2	25

Prev Page Next Page Go to Doc#

Generate Collection

L6: Entry 9 of 25 File: USPT Sep 23, 2003

DOCUMENT-IDENTIFIER: US 6623764 B1
TITLE: Biodegradable targetable microparticle delivery system

Drawing Description Text (32):
FIG. 20 shows the serum IgG antibody subtype responses in mice immunized subcutaneously (S.C.) or orally (I.G.) following various immunization protocols by the recombinant protein rUrease from Helicobacter pylori. Groups of 8 mice were immunized on days 1, 28 and 56 with 250 .mu.L of PBS pH 7.4, containing 10.0 .mu.g (S.C.) or 40.0 .mu.g (I.G.) of rUrease incorporated into PLGpS microparticles or 10.0 .mu.g (S.C.) or 40.0 .mu.g (I.G.) of rUrease formulated in the presence of DC-Chol, CT-X, PCPP or LT incorporated into PLGpS microparticles. Sera was obtained on day +85 and were evaluated for the presence of anti-rUrease IgG antibodies using an enzyme-linked immunosorbent assay (ELISA).

US006623764B1

(12) **United States Patent**
Sokoll et al.

(10) **Patent No.: US 6,623,764 B1**
(45) **Date of Patent: *Sep. 23, 2003**

(54) **BIODEGRADABLE TARGETABLE MICROPARTICLE DELIVERY SYSTEM**

(75) Inventors: **Kenneth K. Sokoll**, Alton (CA); **Pele Chong**, Richmond Hill (CA); **Michel H. Klein**, Willowdale (CA)

(73) Assignee: **Aventis Pasteur Limited**, Toronto (CA)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **09/331,118**

(22) PCT Filed: **Dec. 19, 1997**

(86) PCT No.: **PCT/CA97/00980**

§ 371 (c)(1),
(2), (4) Date: **Aug. 31, 1999**

(87) PCT Pub. No.: **WO98/28357**

PCT Pub. Date: **Jul. 2, 1998**

Related U.S. Application Data

(63) Continuation-in-part of application No. 08/770,850, filed on Dec. 20, 1996, now Pat. No. 6,082,820.

(51) **Int. Cl.**[7] ..... ~~A61K 9/16~~; A61K 47/34; C08G 63/08

(52) **U.S. Cl.** **424/501**; 424/78.37; 528/318; 528/329.1

(58) **Field of Search** 424/426, 443, 424/78.37, 501; 514/772.3; 525/54.11; 528/283, 288, 315, 318, 329.1

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,676,945	A	4/1954	Higgins
3,839,297	A	10/1974	Wasserman et al.
RE30,170	E	12/1979	Goodman et al.
4,855,283	A	8/1989	Lockhoff
5,399,665	A	3/1995	Barrera et al.
5,593,778	A	1/1997	Kondo et al.
5,625,030	A	4/1997	Williams et al.

FOREIGN PATENT DOCUMENTS

EP	600161	6/1994
WO	WO 94/09760	5/1994

OTHER PUBLICATIONS

Levine, M.M. et al—*Lancet*, 340, 1992, 689.
Eldridge, J.H. et al;—*J. Control. Release*, 11, 1990, 205.
Eldridge, J.H. et al—*Mol. Immunol.*, 28, 1991, 287.
O'Hagan, D.T. et al—*Vaccine*, 7, 1989, 213.
Mitsunobu, O.; *Synthesis*, 1981.
Zhou, Q., and Kohn, J., *J. Macromolecules*, 23, 1990, 3300.
Brode, G.L., et al—*J. Macromol. Sci–Chem.*, A6, 1972, 1109.
Kohn, F.E. et al—*J., Eur. Polym. J.*,19, 1983, 1081.
Kohn, F.E. et al—*Journal of Applied Polymer Science*, 29, 1984, 4265.
Kricheldorf, H.R.; and Dunsing, R., *Polymer Bulletin*, 14, 1985, 491.
Kricheldorf, H.R. et al;—*Macromol. Chem. Suppl.*, 12, 1985, 25.
Leenslag, J.W.; et al—*Makromol. Chem.*, 188, 1987, 1809.
Kricheldorf, H.R. et al—*Eur. Polymer J.*, 25, 1989, 585.
Hayashi, T. et al—*Biopolymers*, 29, 1990, 549.
Hayashi, T.; et al—*J. Appl. Polym. Sci.*, 43, 1991, 2223.
Hayashi, T. et al—*Polym. J.*, 5, 1993, 481.
Kohn, J.; and Langer, R., *J. Am. Chem. Soc.*, 109, 1987, 817.
Yonezawa, N.; Toda, F.; Hasegawa, M., *Makromol. Chem. Rapid Commun.*, 6, 1985, 607.
Helder, J.; and Feijen, J., *Makromol. Chem. Rapid Commun.*, 7, 1986, 193.
Veld, P.J. A.; Dijkstra, P.J.; Lochem, J.H. van; and Feigen, J., *Makromol. Chem.*, 191, 1990, 1813.
Langer, R.; Barrera, D.A.; Zylstra, E.; and Lansbury, P.T., *J. Am. Chem. Soc.*, 115, 1993, 11010.
Barrera, D.A.; Zylstra, E.; and Lansbury, P.T., *Macromolecules.*, 28, 1995, 425.
Veld, P.J.A. et al—*J. Polymer Sci.*, 32(6), 1994, 1063.
Reed, A.M. and Gilding, D.K.; *Polymer*, 22, 1981, 494.



First Hit

Generate Collection Print

L6: Entry 1 of 25 File: PGPB Feb 19, 2004

DOCUMENT-IDENTIFIER: US 20040033240 A1
TITLE: Immunological combinations for prophylaxis and therapy of helicobacter pylori pylori infection

Detail Description Paragraph:
[0041] Adjuvants to be used in vaccine formulations for prevention and treatment should provide a "balanced" Th1/Th2 response, a profile likely to be associated with protective responses against H. pylori. The Th1 arm (a "cellular" response) has has been shown to be critical in response to H. pylori infection. The Th2 arm (an "antibody" response) is also thought to be important. Thus, ideally, an adjuvant capable of stimulating both arms of the immune system, together with the correct combination of antigens, administered in the route most suited to eliciting the desired response, are all expected to be important components of a safe, efficacious vaccine for prophylaxis and therapy of H. pylori infection. One such balanced Th1/Th2 adjuvant is DC-Chol (F. Brunel et al. 1999 Vaccine 17: 2192-2203).